Epidermal growth factor receptor (EGFR) antisense transfection reduces the expression of EGFR and suppresses the malignant phenotype of a human ovarian cancer cell line.

  • Authors:
    • K R Brader
    • J K Wolf
    • S Chakrabarty
    • J E Price
  • View Affiliations

  • Published online on: September 1, 1998     https://doi.org/10.3892/or.5.5.1269
  • Pages: 1269-1343
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

An EGFR-expressing clone of the human ovarian cancer line 2774 was transfected with an antisense construct of EGFR to test how suppression of this gene modulates the malignant phenotype. Transfected clones were screened for EGFR expression by Western blot and FACS analysis. Anchorage-independent growth was used to assess the effect of reduced EGFR on the malignant behavior of the cells. Several transfected clones with decreased EGFR (40-50% reduction) were identified. A correlation was noted between reduced EGFR and decreased anchorage-independent growth, with the transfected clones losing the ability to grow in agarose and responsiveness to exogenous EGF. These results suggest that EGFR may be an important factor in the malignant behavior of this ovarian cancer cell line.

Related Articles

Journal Cover

Sep-Oct 1998
Volume 5 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Brader K, Wolf J, Chakrabarty S and Price J: Epidermal growth factor receptor (EGFR) antisense transfection reduces the expression of EGFR and suppresses the malignant phenotype of a human ovarian cancer cell line.. Oncol Rep 5: 1269-1343, 1998.
APA
Brader, K., Wolf, J., Chakrabarty, S., & Price, J. (1998). Epidermal growth factor receptor (EGFR) antisense transfection reduces the expression of EGFR and suppresses the malignant phenotype of a human ovarian cancer cell line.. Oncology Reports, 5, 1269-1343. https://doi.org/10.3892/or.5.5.1269
MLA
Brader, K., Wolf, J., Chakrabarty, S., Price, J."Epidermal growth factor receptor (EGFR) antisense transfection reduces the expression of EGFR and suppresses the malignant phenotype of a human ovarian cancer cell line.". Oncology Reports 5.5 (1998): 1269-1343.
Chicago
Brader, K., Wolf, J., Chakrabarty, S., Price, J."Epidermal growth factor receptor (EGFR) antisense transfection reduces the expression of EGFR and suppresses the malignant phenotype of a human ovarian cancer cell line.". Oncology Reports 5, no. 5 (1998): 1269-1343. https://doi.org/10.3892/or.5.5.1269